Perjeta
Roche Reports 5 Percent CER Growth in Pharmaceutical Sales Driven by Strong Phesgo Uptake
In the first half of the year, sales of the injectable formulation of HER2-targeted agent grew 60 percent at CER, compared to H1 2023.
The study didn't meet its prespecified endpoint but suggests potential activity in HER2-amplified urothelial cancer and cholangiocarcinoma.
Chemo-Free Regimens for Hormone Receptor, HER2-Positive Breast Cancer Show Promise at SABCS
Researchers shared data from two single-arm trials, in which the combination of anti-HER2 treatment, a CDK4/6 inhibitor, and hormone therapy benefited patients with aggressive disease.
Bolt Biotherapeutics Studying BDC-1001 With Genentech's Perjeta in HER2-Positive Breast Cancer
The company is pairing its immune-stimulating antibody conjugate with the monoclonal antibody Perjeta after the combo showed synergistic activity in preclinical research.
Breast Cancer Study Informs Affibody, GE HealthCare's Development Path for HER2 Radiopharmaceutical
Premium
The PET imaging agent 68Ga-ABY-025 could have a leg up over IHC in predicting metastatic breast cancer patients' ability to respond to HER2-targeted treatment.